IL276661B2 - Immunogenic preparation containing staphylococcal antigens - Google Patents
Immunogenic preparation containing staphylococcal antigensInfo
- Publication number
- IL276661B2 IL276661B2 IL276661A IL27666120A IL276661B2 IL 276661 B2 IL276661 B2 IL 276661B2 IL 276661 A IL276661 A IL 276661A IL 27666120 A IL27666120 A IL 27666120A IL 276661 B2 IL276661 B2 IL 276661B2
- Authority
- IL
- Israel
- Prior art keywords
- amino acid
- seq
- immunogenic composition
- composition according
- acid sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1802339.0A GB201802339D0 (en) | 2018-02-13 | 2018-02-13 | Immunogenic composition |
| PCT/EP2019/053463 WO2019158537A1 (en) | 2018-02-13 | 2019-02-12 | Immunogenic composition comprising staphylococcal antigens |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL276661A IL276661A (en) | 2020-09-30 |
| IL276661B1 IL276661B1 (en) | 2023-04-01 |
| IL276661B2 true IL276661B2 (en) | 2023-08-01 |
Family
ID=61731342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276661A IL276661B2 (en) | 2018-02-13 | 2019-02-12 | Immunogenic preparation containing staphylococcal antigens |
Country Status (15)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| CN110511950B (zh) * | 2019-07-29 | 2022-03-08 | 因之彩生物科技(武汉)有限公司 | Pab蛋白在构建具有类伴侣样蛋白作用的融合蛋白表达载体中的应用 |
| EP3777884A1 (en) * | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| US20230045642A1 (en) | 2019-12-19 | 2023-02-09 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
| AU2021262999A1 (en) | 2020-05-01 | 2023-01-19 | Sinocelltech Ltd. | Method for improving immunogenicity of protein/peptide antigen |
| KR20220039610A (ko) | 2020-09-21 | 2022-03-29 | 주식회사 엘지에너지솔루션 | 리튬 이차전지 활성화 방법 및 리튬 이차전지 |
| CN121081612A (zh) * | 2024-05-30 | 2025-12-09 | 江苏坤力生物制药有限责任公司 | 一种金黄色葡萄球菌纳米化抗原、含其的疫苗及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010151544A1 (en) * | 2009-06-22 | 2010-12-29 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens |
| WO2011138361A1 (en) * | 2010-05-06 | 2011-11-10 | Glycovaxyn | Capsular gram-positive bacteria bioconjugate vaccines |
| WO2012003474A2 (en) * | 2010-07-02 | 2012-01-05 | The University Of Chicago | Compositions and methods related to protein a (spa) variants |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2730275T3 (es) * | 2004-09-22 | 2019-11-11 | Glaxosmithkline Biologicals Sa | Composición inmunógena para uso en vacunación contra estafilococos |
| GB0526038D0 (en) | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CA2713241C (en) * | 2008-01-31 | 2022-10-04 | Timothy Foster | Treatment of microbial infections |
| AU2015202532A1 (en) | 2009-04-14 | 2015-06-04 | Novartis Ag | Compositions for immunising against Staphylococcus aureus |
| US20140037650A1 (en) | 2009-07-24 | 2014-02-06 | University Of Chicago | Compositions and methods related to antibodies to staphylococcal proteins isda or isdb |
| JP5793194B2 (ja) | 2010-09-09 | 2015-10-14 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 感染防御ブドウ球菌抗原が関与する方法および組成物 |
| HUE033072T2 (hu) | 2010-12-22 | 2017-11-28 | Wyeth Llc | Staphylococcus aureus antigének immunogén készítményei |
| US9556281B2 (en) * | 2011-08-15 | 2017-01-31 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
| EP2890387A1 (en) * | 2012-08-31 | 2015-07-08 | Novartis AG | Stabilised proteins for immunising against staphylococcus aureus |
| CN106163550A (zh) | 2013-12-04 | 2016-11-23 | 格林考瓦因有限公司 | 通过大肠杆菌中合成的糖蛋白疫苗预防金黄色葡萄球菌感染 |
| MX377794B (es) * | 2014-03-26 | 2025-03-10 | Glaxosmithkline Biologicals Sa | Antigenos estafilococicos mutantes. |
| GB201721582D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
-
2018
- 2018-02-13 GB GBGB1802339.0A patent/GB201802339D0/en not_active Ceased
-
2019
- 2019-02-12 AU AU2019221496A patent/AU2019221496B2/en not_active Ceased
- 2019-02-12 BR BR112020016373-2A patent/BR112020016373A2/pt not_active IP Right Cessation
- 2019-02-12 CA CA3090609A patent/CA3090609A1/en active Pending
- 2019-02-12 AR ARP190100345A patent/AR114627A1/es not_active Application Discontinuation
- 2019-02-12 SG SG11202007676RA patent/SG11202007676RA/en unknown
- 2019-02-12 US US16/968,895 patent/US11426455B2/en active Active
- 2019-02-12 EA EA202091690A patent/EA202091690A1/ru unknown
- 2019-02-12 IL IL276661A patent/IL276661B2/en unknown
- 2019-02-12 WO PCT/EP2019/053463 patent/WO2019158537A1/en not_active Ceased
- 2019-02-12 EP EP19706423.1A patent/EP3752183A1/en not_active Withdrawn
- 2019-02-12 JP JP2020565545A patent/JP2021514387A/ja active Pending
- 2019-02-12 CN CN201980025676.7A patent/CN112153980A/zh active Pending
- 2019-02-12 MX MX2020008454A patent/MX2020008454A/es unknown
- 2019-02-12 KR KR1020207025858A patent/KR20200121825A/ko not_active Withdrawn
-
2022
- 2022-07-20 US US17/869,055 patent/US20230052495A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010151544A1 (en) * | 2009-06-22 | 2010-12-29 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens |
| WO2011138361A1 (en) * | 2010-05-06 | 2011-11-10 | Glycovaxyn | Capsular gram-positive bacteria bioconjugate vaccines |
| WO2012003474A2 (en) * | 2010-07-02 | 2012-01-05 | The University Of Chicago | Compositions and methods related to protein a (spa) variants |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202007676RA (en) | 2020-09-29 |
| KR20200121825A (ko) | 2020-10-26 |
| EA202091690A1 (ru) | 2020-11-27 |
| BR112020016373A2 (pt) | 2020-12-15 |
| JP2021514387A (ja) | 2021-06-10 |
| CA3090609A1 (en) | 2019-08-22 |
| IL276661A (en) | 2020-09-30 |
| IL276661B1 (en) | 2023-04-01 |
| AR114627A1 (es) | 2020-09-30 |
| EP3752183A1 (en) | 2020-12-23 |
| US20230052495A1 (en) | 2023-02-16 |
| GB201802339D0 (en) | 2018-03-28 |
| US20210023192A1 (en) | 2021-01-28 |
| AU2019221496A1 (en) | 2020-08-27 |
| AU2019221496B2 (en) | 2022-12-08 |
| US11426455B2 (en) | 2022-08-30 |
| MX2020008454A (es) | 2021-03-25 |
| CN112153980A (zh) | 2020-12-29 |
| WO2019158537A1 (en) | 2019-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514387A5 (cg-RX-API-DMAC7.html) | ||
| Kim et al. | Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1–KLH and GD3–KLH conjugates | |
| JP2016502551A5 (cg-RX-API-DMAC7.html) | ||
| ES2276476T3 (es) | Vacunas de emulsion de aceite en agua contra la hepatitis b. | |
| CA2190344C (en) | Quillaja saponin adjuvant and vaccine formulation containing same | |
| EP2026841B1 (en) | Conjugation process for pnag and a carrier protein | |
| HRP20190711T1 (hr) | Imunogeni pripravak | |
| EP1267908B1 (en) | Vaccine for the treatment of atherosclerosis | |
| US9775898B2 (en) | Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses | |
| RU2007145052A (ru) | Композиции пептидного конъюгата и способы для профилактики и лечения болезни альцгеймера | |
| HRP20120136T1 (hr) | Imunogeni pripravak koji sadrži adjuvans | |
| HU229968B1 (hu) | Sztreptokokkusz oltóanyag | |
| AU719084B2 (en) | Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen | |
| AR009958A1 (es) | Composiciones adyuvantes; vacunas formuladas con dichas composiciones; el uso de dichas composiciones en la preparacion de vacunas y procedimiento parapreparar dichas vacunas. | |
| EA000839B1 (ru) | Липосомальная вакцинная композиция, применение липосомальной вакцинной композиции и способ лечения млекопитающего | |
| BRPI0312472B8 (pt) | composição compreendendo dois complexos iscom diferentes | |
| BR0107679A (pt) | Vacina de vesìcula de membrana externa (omv) compreendendo proteìnas de membrana externa do grupo sérico b de neisseria meningitidis | |
| JP2004538330A (ja) | 免疫応答増強剤 | |
| US10159729B2 (en) | Antigen and method for production thereof | |
| JP2017511327A5 (cg-RX-API-DMAC7.html) | ||
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| JP2017511324A5 (cg-RX-API-DMAC7.html) | ||
| KR20200121825A (ko) | 포도상구균 항원을 포함하는 면역원성 조성물 | |
| CA2409406A1 (en) | Qs-21 and il-12 as an adjuvant combination | |
| RU2015106742A (ru) | Композиции, содержащие химерные молекулы ospa и способы их применения |